Vascular Intervention Strategies Trial for Alzheimer's
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Angiotensin Receptor Blockers (ARBs), Hydrophilic Statins or Non-Statin Alternative.
- Who it may be relevant to
- Registry conditions: Hypertension, Hypercholesterolemia, Dementia Risk Factors. Basic parameters: 50 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Vascular Intervention Strategies Trial for Alzheimer's (VISTA)
Overview
The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. All participants will receive angiotensin receptor blockers (ARBs) for high blood pressure, and hydrophilic statins (or a non-statin alternative) for high cholesterol over a six-month period.
Interventions
- Drug Angiotensin Receptor Blockers (ARBs)
Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes blood pressure management with angiotensin receptor blockers (ARBs). - Drug Hydrophilic Statins or Non-Statin Alternative
Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes cholesterol management with hydrophilic statins or a non-statin alternative if statins are not appropriate.
Primary outcome measures
- Blood Pressure Control [Time frame: Baseline to 6 months]
Secondary outcome measures (2)
- Lipid Level Changes [Time frame: Baseline to 6 months]
- Feasibility Metrics [Time frame: Study duration (6 months)]
Eligibility criteria
Inclusion criteria
- APOE ε4 carrier (homozygote or heterozygote)
- LDL-C of 100-250 mg/dL
- Systolic blood Pressure (SBP) 130-180 mm Hg
- Age 50-75 years
- Fluency in English
- No dementia based on medical record review
- Male or post-menopausal female
Exclusion criteria
- One minute standing SBP < 110 mm Hg
- Arm circumference prevents from accurate BP measurement with use of available devices
- Lost weight of > 10% unintendedly (within the past 6 months),
- Contraindications to blood pressure and cholesterol lowering medications
- Use of medications prescribed for dementia (e.g., aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, memantine)
- Evidence of dementia based on medical record review
- Living in a skilled nursing or rehabilitation facility
- Receiving palliative or hospice care
- Bipolar illness or schizophrenia
- Drug or alcohol disorder
- Receiving chronic opioid therapy
- Any significant neurological disease (e.g., Parkinson's disease, amyotrophic lateral sclerosis, or multiple sclerosis)
- Severe loss of visual, hearing or communication ability
- Organ transplant
- History of stroke, symptomatic HF or left ventricular ejection fraction < 35%
- ESRD or eGFR < 20 ml/min /1.73m2
- Does not consent to be contacted or to have their medical record reviewed for research purposes
- Concurrent participation in another clinical trial
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
United States · 1 center
- Clinical Sciences Building (CSC) — Los Angeles
Identifiers
NCT: NCT07447206 · HS-24-00340 · PG1040967